{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:58:42Z","timestamp":1790805522575,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.autrev.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T01:31:37Z","timestamp":1516152697000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"17","author":[{"given":"Merav","family":"Lidar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Giat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Garelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Steinberg-Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.01.003_bb0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0025","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0030","first-page":"399","article-title":"Ipilimumab adjuvant therapy in melanoma","volume":"376","author":"Eggermont","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.autrev.2013.01.001","article-title":"Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis","volume":"12","author":"Cutolo","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.003_bb0040","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.003_bb0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2018.01.003_bb0065","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.4049\/jimmunol.177.9.6062","article-title":"Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions","volume":"177","author":"Markel","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0070","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/1535-7163.MCT-11-0526","article-title":"Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions","volume":"11","author":"Ortenberg","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.autrev.2018.01.003_bb0075","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2018.01.003_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.003_bb0090","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","article-title":"Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity","volume":"12","author":"Gianchecchi","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.003_bb0095","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fimmu.2017.00851","article-title":"Extracellular vesicles transfer the receptor programmed death-1 in rheumatoid arthritis","volume":"8","author":"Greisen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2018.01.003_bb0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2015.11.004","article-title":"Role of extracellular vesicles in autoimmune diseases","volume":"15","author":"Turpin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.003_bb0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.autrev.2017.05.025","article-title":"Targeting the programmed cell death-1 pathway in rheumatoid arthritis","volume":"16","author":"Sandigursky","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.003_bb0110","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2018.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.01.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1107699","article-title":"The controversial role of TNF in melanoma","volume":"5","author":"Donia","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2018.01.003_bb0125","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.177.5.1391","article-title":"Enhancement of experimental metastasis by tumor necrosis factor","volume":"177","author":"Orosz","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2018.01.003_bb0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.003_bb0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.003_bb0140","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.003_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2018.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.003_bb0155","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.autrev.2018.01.003_bb0160","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T17:56:08Z","timestamp":1535133368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218300107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1568997218300107"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}